This study integrated multiple bioinformatic analyses and experimental validations and found that CCL2 was significantly overexpressed in GBM, and can be used as an independent prognostic factor to predict the OS and PFS of GBM patients. This evidence concerns the gene CCL2 and glioblastoma.